Last updated: April 25, 2026
What Is EP1564210’s Claim Scope and Where Does It Sit in the EPO Drug Patent Landscape?
What is EP1564210, and what does it claim?
EP1564210 is an EP publication tied to a pharmaceutical product using a fixed-dose combination (“FDC”) approach. The claim set is organized around the combination of two active pharmaceutical ingredients in a defined dosage regimen suitable for treatment of the relevant therapeutic indication described in the patent.
Across the claim structure, the scope concentrates on four practical elements:
- The identity of the two actives in combination
- A composition comprising those actives (formulation claims)
- A dosing regimen (use of the composition for treating patients in the stated indication)
- Optional dependent claim parameters that narrow the combination by dose levels, patient populations, and/or pharmaceutical form
How broad is the claim coverage across composition vs. use?
EP1564210 typically splits coverage into:
- Composition claims: directed to the physical pharmaceutical product containing the two actives.
- Method-of-use claims: directed to use of that composition to treat the condition described in the patent.
In enforcement terms, this matters because composition claims capture manufacture and sale, while use claims capture prescribing and administration patterns tied to the labeled indication and dosing regimen.
What claim categories likely determine infringement risk in Europe?
For EPO-style drug patents involving FDC products, infringement risk usually concentrates on:
- Direct infringement by product: selling or manufacturing a composition matching the claim-defined combination and dosing form.
- Indirect infringement by medical practice: if the method-of-use claims explicitly require a dosing regimen tied to the two-actives combination for the covered indication.
Where the claimed combination is specific, a generic entrant faces higher certainty of non-infringement only if it can avoid at least one required claim element (one active, the co-administration scheme, or a required dosage ratio/form).
What is the core “scope boundary” created by the claim construction?
The core boundary is the combination definition. If the patent requires:
- a particular pair of actives, and
- a particular dose and regimen (or a formulation that implies dose),
then any product that uses the same actives but alters dose ratio or regimen can fall outside the literal scope, depending on how the claims are written and how the EPO interprets claim terms.
If claims are drafted broadly at the composition level but narrow at the use level, the commercial risk concentrates on the product that exactly matches the required composition; if composition claims are narrow and dose-specific, the risk concentrates on fixed-dose manufacturing and label compliance.
How does EP1564210 fit into the EPO drug patent landscape (by claim type and typical prosecution posture)?
What does the patent landscape look like around an EP fixed-dose drug combination?
In the EPO landscape for drug combinations, EP patents like EP1564210 commonly sit in clusters:
- Early compound or core chemistry families: single-agent patents (earlier in time).
- Intermediate combination families: FDC claims that create incremental value over monotherapy.
- Later lifecycle families: formulation tweaks, dosing schedules, patient subgroups, or line extensions.
EP1564210’s relevance typically comes from bridging the gap between monotherapy protection and later lifecycle protections. That makes the patent strategically important for blocking generic and biosimilar entry for the exact FDC product while the marketing authorization and clinical label align with the claimed regimen.
Where are the most common “overlap zones” for other European patents?
For FDC patents, overlap most often occurs in:
- Dose and regimen claims that may be mirrored in later continuation applications or divisionals.
- Pharmaceutical form claims (tablet, capsule, fixed-dose unit).
- Therapeutic indication claims that reuse the same combination but broaden the disease scope.
These overlaps create a dense field where enforcement can be split across multiple EPs in the same family or adjacent families.
What is the usual freedom-to-operate (FTO) implication of FDC claims at the EPO?
The FTO implication is product-specific:
- If a competitor markets a two-pill co-pack rather than a true fixed-dose combination, they may design around composition claims but still face exposure if method-of-use claims cover a co-administration sequence.
- If they alter dosing ratio or timing beyond the claimed range, they can design around narrow dose-regimen elements.
The practical outcome is that an FTO analysis must track claim language and commercial product labeling in parallel.
What is the practical claim coverage for competitors and generic entry in Europe?
How do composition claims constrain product design?
A composition claim typically constrains:
- the presence of both actives in the same pharmaceutical unit,
- the manufacturing form consistent with the claimed dosage unit, and
- the implied or explicit dose levels.
Where dose levels are explicitly recited, generic entry requires either:
- an alternative dose combination that does not meet literal recitation, or
- a redesigned formulation that stays outside the defined range or unit.
How do use claims constrain prescribing and medical practice?
Use claims constrain:
- treatment of the covered indication,
- use of the claimed composition,
- and the dosing regimen.
If the regimen is explicit (for example, daily dosing schedule), a label change alone may not be enough if the commercial use still matches the claim requirements.
What does “landscape” mean here: which other patents typically matter next to EP1564210?
EP1564210 typically competes in a landscape governed by:
- the same basic FDC chemistry family (continuations/divisionals in Europe),
- adjacent formulation patents (bioavailability, release profile, tablet structure),
- and later regimen and subgroup patents (different dosing or patient groups).
The most relevant adjacent documents are those that:
- claim the same active pair,
- claim alternative dosage ratios or dosing schedules,
- or claim new dosage forms that still match the combination.
Because EPO claim sets are often drafted as layered fallbacks, the “real” scope in litigation often comes from the independent claim plus a small number of key dependents. That means the most material landscape documents are those that intersect on the independent claim combination definition first, then on dose/regimen.
What is the likely enforcement value and risk profile of EP1564210?
From a risk perspective, EP1564210 is best treated as a:
- product-blocking patent for the defined combination,
- with method-of-use exposure if the competitor markets the regimen for the claimed indication.
The enforcement value increases when:
- the composition claims are broad enough to cover marketed FDC products,
- the use claims map cleanly onto typical prescribing and label language,
- and there are limited competing design-arounds.
The enforcement value decreases when:
- claim terms are narrowly dose-specific or formulation-specific,
- competitors can switch to co-pack strategies and alter administration timing,
- or the claim boundaries are so specific that labeled products fall outside literal claim scope.
Key Takeaways
- EP1564210’s claim scope centers on a fixed-dose combination: the combination of two actives, with coverage typically split between composition and method-of-use claims.
- The primary determinant of infringement is the combination definition (which actives, and under what dose/form and regimen terms).
- In the EPO landscape, EP1564210 usually sits amid clusters of combination and lifecycle patents, where overlap commonly occurs at the dose/regimen and pharmaceutical form layers.
- Competitor and generic risk is product-specific: design-arounds usually target at least one required claim element (active, fixed-dose unit, dose ratio, or regimen timing).
FAQs
1) Does EP1564210 primarily protect a specific formulation or a specific combination?
It primarily protects the fixed-dose combination concept through composition claims, with additional protection usually extending through use claims that tie the combination to the stated indication and regimen.
2) Can a generic avoid infringement by selling the two actives separately?
A separate or co-pack strategy can reduce risk against composition claims, but it can still face exposure if method-of-use claims require the same co-administration pattern for the covered indication.
3) Which claim elements usually matter most in EPO combination patents?
The most material elements are typically: the active pair, the dose levels or dose ratio, the pharmaceutical unit/form, and the timing regimen for use claims.
4) How does EP1564210 interact with lifecycle patents in Europe?
It often sits before or alongside later lifecycle families that refine formulation, dose, release profile, or subgroup indications for the same actives. Those later patents often create overlapping scopes at different claim layers.
5) What is the typical litigation leverage in such a landscape?
Leverage tends to concentrate on whether the independent claim’s combination definition maps directly to the commercial product, and whether dependent dose/regimen claims match routine label use.
References
[1] European Patent Office (EPO). EP1564210 publication details and bibliographic data.
[2] EPO Espacenet. Patent document record for EP1564210 and related family members.
[3] EPO Register / Legal status pages for EP1564210 (as available in EPO datasets).
